1. All Products
  2. LPV 100mg / r 25mg, tab.
Public Pricelist

LPV 100mg / r 25mg, tab.

https://medicalguidelines.msf.org/en/node/433
https://unicat.msf.org/cat/product/12135
NST DORALPVR4T-

Outdated Article

Former Code(s): -X DORALPRF1T2 DORAZBD0481 DORAZBD0482 DORAZFR0511 DORAZYN1057
6.4.2.3 - Protease inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AR10
Anatomical Therapeutic Chemical Classification according to WHOCC
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
https://unicat.msf.org/web/image/product.template/572453/image_1920?unique=7144ba3

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

LOPINAVIR (LPV) / RITONAVIR (r)

Therapeutic Action

Fixed-dose combination (FDC) of two antiretrovirals, protease inhibitors (PI)

Indications

HIV infection

Lopinavir/Ritonavir combinations may be used as an alternative when Darunavir/Ritonavir cannot be used.

The combination of Darunavir/Ritonavir is the preferred boosted protease inhibitor option for ART when a protease inhibitor is required.

Instructions for use

LPV 40mg / r 10mg, granules, sachet (DORALPVR1G-) is intended for paediatric use:

  • pour the granules into a small amount of breast milk, water or soft foods
  • administer immediately (within a maximum of 2 hours after preparation).

For adults, DRV eq. 400mg base / r 50mg, tablet (DORADRVR45T) is first choice over LPV 100mg / r 25mg and LPV 200mg / r 50mg, tablets.

Storage

Below 25ºC - Protect from sunlight - Protect from humidity